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OBJECTIVES We sought to compare the responses of patients with pulmonary hypertension from primary
and secondary causes (PPH and SPH, respectively) to inhaled nitric oxide (iNO) in the
cardiac catheterization laboratory.
BACKGROUND Pulmonary hypertension can lead to right ventricular pressure overload and failure. Although
vasodilators are effective as therapy in patients with PPH, less is known about their role in
adults with SPH. Inhaled nitric oxide can accurately predict the response to other vasodilators
in PPH and could be similarly utilized in SPH.
METHODS Forty-two patients (26 to 77 years old) with pulmonary hypertension during cardiac
catheterization received iNO. Demographic and hemodynamic data were collected. Their
response to iNO was defined by a decrease of $20% in mean pulmonary artery (PA) pressure
or pulmonary vascular resistance (PVR).
RESULTS Mean PA pressures and PVR were lower during nitric oxide (NO) inhalation in all patients
with pulmonary hypertension. Seventy-eight percent of patients with PPH and 83% of
patients with SPH were responders to iNO. A trend was seen toward a greater response with
larger doses of NO in patients with SPH. Nitric oxide was a more sensitive predictor of
response (79%), compared with inhaled oxygen (64%), and was well tolerated, with no
evidence of systemic effects. Elevation in right ventricular end-diastolic pressure appeared to
predict poor vasodilatory response to iNO.
CONCLUSIONS Nitric oxide is a safe and effective screening agent for pulmonary vasoreactivity. Regardless of
etiology of pulmonary hypertension, pulmonary vasoreactivity is frequently demonstrated
with the use of NO. Right ventricular diastolic dysfunction may predict a poor vasodilator
response. (J Am Coll Cardiol 2000;36:2204–11) © 2000 by the American College of
Cardiology
Primary pulmonary hypertension (PPH) is a devastating
disease affecting a young, predominantly female population
in the prime of their lives. Progressive dyspnea, hypoxemia
and chest pain eventually give way to ascites, peripheral
edema and generalized anasarca (massive edema). The
development and demonstrated efficacy of pulmonary vaso-
dilating agents, including calcium channel blockers and,
more recently, continuous intravenous prostacyclin has
given hope to these unfortunate patients (1–3).
Demonstration of a positive response to vasodilating
agents in PPH has been shown to correlate with an
improved long-term clinical outcome (4). A number of
vasodilating agents have been used in the cardiac catheter-
ization laboratory, including adenosine, atrial natriuretic
peptide, amrinone, isoproterenol, tolazoline, nitroprusside,
nitroglycerin, hydralazine, prostacyclin and calcium channel
antagonists, in an attempt to assess these patients and
decide on long-term therapy.
Inhaled nitric oxide (iNO) has many characteristics that
render it an excellent vasodilator for the pulmonary vascular
bed. Because it is delivered as a gas and is rapidly inactivated
when bound to hemoglobin, the effects remain local, and
hypotension is exceedingly rare. Its short half-life also
permits rapid discontinuation, if necessary.
Nitric oxide (NO) is critical in the regulation of intrinsic
pulmonary vascular tone (5), and pulmonary hypertension,
at least in part, results from a derangement in the regulation
of NO. Most of the published data on the use of iNO in the
catheterization laboratory relates to patients with PPH or to
children with congenital heart defects that result in in-
creased pulmonary vascular blood flow and resistance. How-
ever, most patients with pulmonary hypertension in the U.S.
are a heterogeneous group of adults with progressive pul-
monary and cardiac disease (secondary pulmonary hyper-
tension [SPH]) (6). These patients are also at risk for
progressive right ventricular pressure overload and eventu-
ally cor pulmonale. As in the PPH population, this com-
plication can significantly affect quality of life and hasten
mortality. Unfortunately, the only therapy demonstrated to
prolong survival in patients with end-stage lung disease is
inhaled oxygen (7,8).
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The efficacy and safety of iNO in adults with SPH has
not yet been fully clarified. The objective of this study was
to compare the responses of patients with PPH and SPH to
iNO. Previous studies have been divided concerning the
ideal dose of NO and the absence or presence of a dose
response; we sought to determine if a dose response existed
(9–13).
METHODS
Study group. Patients with pulmonary hypertension (de-
fined by a mean pulmonary artery [PA] pressure
$25 mm Hg at the time of cardiac catheterization) were
enrolled between November 1998 and November 1999.
Written, informed consent was obtained by using a protocol
approved by Duke University Medical Center’s Investiga-
tions Review Board. Patients with PPH, as defined by the
National Institutes of Health (NIH, Bethesda, Maryland)
criteria (14), had previously undergone extensive evaluation
to exclude any secondary causes of their pulmonary hyper-
tension before cardiac catheterization. Patients underwent
cardiac catheterization expressly for vasodilator testing or as
part of their diagnostic work-up before a further interven-
tion (i.e., lung transplantation evaluation or before congen-
ital defect repair). Forty-two patients had complete hemo-
dynamic assessment and vasodilator testing with NO.
Hemodynamic assessment. All studies were conducted in
the fasting state with minimal sedation. If the patient was
taking oral vasodilating drugs, this was noted, but doses
were not withheld. If left heart catheterization was per-
formed, all contrast injections were performed before base-
line hemodynamic assessment. Right heart catheterization
was performed using a single end-hole, balloon flotation
catheter (Bard Pulmonary Wedge Catheter, Medtronic,
Minneapolis, Minnesota). Baseline hemodynamic measure-
ments included mean right atrial pressure, right ventricular
systolic and diastolic pressures, PA systolic, diastolic and
mean pressures, mean pulmonary capillary wedge pressure
and femoral artery systolic, diastolic and mean pressures.
Repeat measurements during drug delivery included PA
systolic, diastolic and mean pressures, mean pulmonary
capillary wedge pressure and femoral artery systolic, diastolic
and mean pressures.
Blood samples were obtained from the main PA and
femoral artery for calculation of the cardiac output, using an
assumed Fick method. In patients with an intracardiac
shunt, two right heart catheters were placed, and a blood
sample of the superior vena cava was obtained to estimate
the mixed venous oxygen saturation. Systemic and pulmo-
nary vascular resistances (SVR and PVR) were calculated
using standard hemodynamic equations and are presented in
absolute (Wood) units.
NO delivery protocol and vasodilator response. The
techniques for delivery of NO have been well described
previously (15). Nitric oxide gas (INO Therapeutics, Mad-
ison, Wisconsin) of medical-grade quality and conforming
to Food and Drug Administration standards was used. A
specialized delivery device (INOvent Delivery System,
Ohmeda Inc., Madison, Wisconsin) delivered NO from
source tanks to achieve proper dosing. Flow rates were
maintained at a rate greater than the patients’ minute
ventilation through a one-way valve into a specially designed
face mask. Levels of NO, oxygen and nitrogen dioxide
(NO2) were continuously monitored throughout the proce-
dure from a sampling port just proximal to the airway.
Because of previous studies demonstrating a negligible
amount of methemoglobinemia with short-term inhalation
of larger doses of NO (16), methemoglobin levels were not
routinely measured.
All patients received iNO at doses of 10, 20 and 40 parts
per million (ppm). Five minutes was allowed at each iNO
dose before hemodynamic assessment was undertaken, and
PA and femoral artery blood samples were drawn for Fick
cardiac output determination. Repeated measurements
showed a maximal response within this period, with very
little variability between measures. Patients could subse-
quently receive 100% oxygen by a non-rebreather face mask
at the discretion of the performing physician.
A significant response to vasodilator testing was defined
as a drop in the mean PA pressure of $20% or a decrease of
$20% in PVR.
Statistical analysis. Data are presented as the mean
value 6 SD for continuous variables, and as the number
(percentage) for discrete variables. Comparison of dichoto-
mous variables was performed using the chi-square test or
the Fisher exact test, as appropriate. Comparisons of the
change from baseline in individual measures were made
using the paired t tests. The dose–response curves for PVR
and mean PA pressures were evaluated by comparing
measures at baseline, 10 ppm, 20 ppm and 40 ppm for PPH
and SPH, using univariate repeated measures techniques.
For each outcome, a model was developed that included as
covariates the pulmonary hypertension type (primary vs.
secondary), the intrasubject effect of PPH versus SPH, the
dose and the interaction between pulmonary hypertension
type and dose. Contrast tests were used to examine the
change in outcome with increments in dose. Changes from
baseline to 10 ppm, from 10 to 20 ppm and from 20 to 40
ppm were tested for patients with PPH and SPH separately.
To correct for multiple comparisons, a Bonferroni correc-
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tion was applied, and significance was declared at p , 0.008
(0.05/6) for each outcome. For all other individual compar-
isons, statistical significance was assumed at p , 0.05. All
analyses were performed using SAS (SAS Institute, Cary,
North Carolina).
RESULTS
Patient group. Forty-three patients were enrolled in the
protocol between November 1998 and November 1999.
One patient was unable to tolerate the face mask because of
anxiety and withdrew from the study. Of the remaining 42
patients, 18 had PPH (43%) and 24 had SPH (57%). The
patients’ ages ranged from 26 to 77 years.
The etiologies of pulmonary hypertension in the SPH
group are listed in Table 1. Intrinsic pulmonary disease was
the cause in 17 patients (71%), and chronic obstructive
disease was the cause in 8 (33%) of 24 patients. Five patients
(21%) with atrial septal defects (four with secundum atrial
septal defect and one with sinus venosus atrial septal defect
with an anomalous pulmonary vein) underwent vasodilator
testing to evaluate their potential for vasoreactivity.
Demographic data and baseline hemodynamic variables.
Baseline demographic data (Table 1) did not differ signifi-
cantly between the two groups. A trend was seen toward
poorer functional class in the PPH group compared with the
SPH group (mean New York Heart Association [NYHA]
congestive heart failure class 2.94 vs. 2.55, respectively; p 5
0.06). More patients with SPH were taking agents with
potential pulmonary vasodilating effects (nifedipine, amlo-
dipine, diltiazem, verapamil and isosorbide dinitrate), with
the primary indication of systemic hypertension. The mean
PA and aortic pressures did not differ between patients
taking vasodilators and those not taking vasodilators. Right
heart pressures tended to be slightly higher in patients with
PPH (Table 1), but did not reach statistical significance.
Patients with SPH had significantly higher pulmonary
capillary wedge pressures (13.8 vs. 10.5 mm Hg, p 5 0.03)
and greater cardiac output (5.15 vs. 4.12 liters/min, p 5
0.03). The PVR was higher in the PPH group (11.3 vs. 6.2
Wood units, p 5 0.02).
Response to NO inhalation. Fourteen (78%) of 18 pa-
tients with PPH were responders and 20 (83%) of 24
patients with SPH were responders to iNO (Table 2) (p 5
0.706 for comparison between the groups). All doses of NO
(10, 20 and 40 ppm) significantly lowered mean PA
pressures in both groups (Table 3). The greatest decrement
in PA pressure occurred with the lowest dose of drug.
Patients with PPH had the majority of their vasoreactive
response at 10 ppm of NO, with little additional vasodila-
tion apparent at the higher doses. Of interest, patients with
SPH had an additional vasodilatory response at each higher
incremental dose (Fig. 1). At 10 ppm of NO, 13 (54%) of
24 patients with SPH were identified as responders. This
increased to 15 (63%) of 24 patients with 20 ppm of NO
and 20 (83%) of 24 patients with 40 ppm of NO. In
contrast, 12 (67%) of 18 patients with PPH were responders
at 10 ppm; and 20 and 40 ppm only increased the number
of responders to 14 (78%) of 18 patients.
Because more patients in the SPH group were taking
vasodilators, the response to NO was compared between
patients taking vasodilators at baseline (diltiazem, vera-
pamil, amlodipine, nifedipine and isosorbide dinitrate) and
patients not taking vasodilators. No discernable difference in
vasodilator response was seen.
Because right ventricular dysfunction may provide a
surrogate for chronicity or severity of disease, right ventric-
ular end-diastolic pressure (RVEDP) was compared with
the extent of mean PA pressure improvement during inha-
lation of 40 ppm of NO. No patient experienced a signifi-
cant ($20%) decrease in PA pressure if their RVEDP
exceeded 20 mm Hg. With RVEDP #10, 9 (82%) of 11
patients experienced a significant decrease in PA pressure.
Of the patients with intermediate RVEDP (12 to
20 mm Hg), 68% experienced a response.
When hemodynamic variables at 40 ppm of iNO were
compared with baseline values (Table 4), significant lower-
ing of the mean PA pressure and PVR was noted in both
groups. The aortic and PA saturations increased in both
groups, as well. No effect on the systemic pressures or SVR
was noted in either group. The cardiac output between
baseline and peak iNO concentration also did not signifi-
cantly change in either group.
Inhaled NO was well tolerated, and no complications
(such as bradycardia, hypotension, chest pain or altered
Table 1. Baseline Clinical and Hemodynamic Data of Patients
Receiving NO
PPH
(n 5 18)
SPH
(n 5 24)
p
Value
Demographic data
Age (yrs) 55 6 14 55 6 11 0.919
Female (%) 78% 67% 0.506
Pulmonary vasodilator
therapy (%)
33% 54% 0.179
NYHA functional class 2.94 6 0.64 2.55 6 0.67 0.064
Hemodynamic data
Mean RAP (mm Hg) 10.4 6 6.3 12.1 6 4.6 0.306
Systolic RVP (mm Hg) 78.3 6 30.7 66.4 6 20.5 0.141
Diastolic RVP (mm Hg) 13.6 6 7.0 15.3 6 6.8 0.438
Mean PAP (mm Hg) 51.5 6 19.8 42.8 6 11.5 0.106
Mean PCWP (mm Hg) 10.5 6 3.4 13.8 6 6.1 0.032
Mean AoP (mm Hg) 105.2 6 15.8 103.2 6 14.2 0.676
Cardiac output (liters/min) 4.1 6 1.1 5.2 6 1.8 0.025
PVR (Wood U) 11.3 6 8.2 6.2 6 3.8 0.022
SVR (Wood U) 24.0 6 5.7 20.8 6 6.8 0.108
Oxygen saturation (%)
PA 60.3 6 10.4 66.2 6 10.6 0.078
Aortic 91.2 6 4.8 92.4 6 6.2 0.050
Data are presented as the mean value 6 SD or percentage of patients.
AoP 5 aortic pressure; NYHA 5 New York Heart Association; PAP 5
pulmonary artery pressure; PCWP 5 pulmonary capillary wedge pressure; PPH 5
primary pulmonary hypertension; PVR 5 pulmonary vascular resistance; RAP 5
right atrial pressure; RVP 5 right ventricular pressure; SPH 5 secondary pulmonary
hypertension; SVR 5 systemic vascular resistance.
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mental state) were apparent in any patient receiving iNO.
Inspired levels of NO2 (a toxic metabolite of NO) were
closely monitored during NO inhalation and did not exceed
1.0 ppm, well below reported toxic levels (17).
Response to 100% oxygen by face mask versus iNO.
Fourteen patients (five with PPH and nine with SPH) also
received a trial of 100% oxygen by a non-rebreather face
mask. Comparable data for these patients with 40 ppm of
iNO versus 100% oxygen are listed in Table 5.
Overall, 64% of patients were responders ($20% decrease
in mean PA pressure or $20% decrease in PVR) to 100%
oxygen, and 79% were responders to iNO. Three of the
patients who did not respond to oxygen responded to NO.
One of the patients who did not respond to NO responded
to oxygen.
DISCUSSION
In 1980, Furchgott and Zawadzki (18) first described the
importance of an intact endothelium in relation to the
regulation of vascular smooth muscle tone. The
endothelium-derived relaxation factor involved in this reg-
ulation was identified as NO in 1987 (19). Since that time,
an explosion in NO research has led to a clearer understand-
ing of the importance of this molecule in normal and
abnormal human physiology.
Nitric oxide has been demonstrated to be an important
intercellular and intracellular messenger molecule in virtu-
ally every organ in the body (20). It regulates basal systemic
and pulmonary artery tone in healthy humans (21–23), and
experimental models of pulmonary hypertension can be
Table 2. Vasodilator Response to Inhaled NO
Diagnosis
No. of
Patients
PAP*
Responders
PVR†
Responders
PVR
or PAP
PVR
and PAP
PPH 18 12 (67%) 13 (72%) 14 (78%) 11 (61%)
SPH 24 15 (63%) 18 (75%) 20 (83%) 13 (54%)
Intrinsic pulmonary disease 17 10 (59%) 14 (78%) 15 (82%) 9 (53%)
COPD 8 4 (50%) 6 (75%) 7 (88%) 3 (38%)
Pulmonary fibrosis 3 2 (67%) 3 (100%) 3 (100%) 2 (67%)
Sarcoidosis 2 1 (50%) 2 (100%) 2 (100%) 1 (50%)
CREST syndrome 3 2 (67%) 2 (67%) 2 (67%) 2 (67%)
Methotrexate toxicity 1 1 (100%) 1 (100%) 1 (100%) 1 (100%)
Cardiac disease 7 5 (71%) 4 (57%) 5 (71%) 4 (57%)
Peripheral PA stenosis 1 1 (100%) 0 (0%) 1 (100%) 0 (0%)
Mitral regurgitation 1 1 (100%) 1 (100%) 1 (100%) 1 (100%)
Atrial septal defect 5 3 (60%) 3 (60%) 3 (60%) 3 (60%)
* Pulmonary artery pressure (PAP) response to inhaled nitric oxide is defined by a decrease in mean pulmonary artery pressure
of $20%.
† Pulmonary vascular resistance (PVR) response is defined by a decrease in PVR of $20%. Because of controversy regarding
the true definition of the response to a pulmonary vasodilator, data for the various reported definitions are listed. Data are
presented as number (%) of patients.
COPD 5 chronic obstructive pulmonary disease; CREST 5 variant of scleroderma; PA 5 pulmonary artery; PAP 5
pulmonary artery pressure; PVR 5 pulmonary vascular resistance; PPH 5 primary pulmonary hypertension; SPH 5 secondary
pulmonary hypertension.
Table 3. Response of Patients to Each Administered Dose of Inhaled NO
PPH Group SPH Group All Patients
Baseline
Mean PAP (mm Hg) 51.5 6 4.7 42.8 6 2.4 46.5 6 2.5
PVR (Wood U) 11.3 6 1.9 6.2 6 0.8 8.4 6 1.0
100 ppm iNO
Mean PAP (mm Hg) 42 6 4.1 37.1 6 2.5 39.3 6 2.3
10 ppm iNO vs. baseline ,0.001 ,0.001 ,0.001
PVR (Wood U) 8.4 6 1.6 5.0 6 0.7 6.5 6 0.8
10 ppm iNO vs. baseline ,0.001 ,0.001 ,0.001
20 ppm iNO
Mean PAP (mm Hg) 40.8 6 4.3 35.6 6 2.4 37.9 6 2.3
20 ppm iNO vs. 10 ppm iNO 0.223 0.156 0.065
PVR (Wood U) 8.1 6 1.6 4.6 6 0.6 6.2 6 0.8
20 ppm iNO vs. 10 ppm iNO 0.536 0.275 0.236
40 ppm iNO
Mean PAP (mm Hg) 40.1 6 4.5 33.8 6 2.3 36.5 6 2.3
40 ppm iNO vs. 20 ppm iNO 0.542 0.082 0.110
PVR (Wood U) 8.1 6 1.9 4.4 6 0.6 6.0 6 0.9
40 ppm iNO vs. 20 ppm iNO 0.990 0.467 0.623
Data are presented as the mean value 6 SD, with p value below.
iNO 5 inhaled nitric oxide; ppm 5 parts per million; other abbreviations as in Table 1.
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created through NO deprivation and inhibition (24,25).
Nitric oxide was first administered to patients with pulmo-
nary hypertension in 1991 (26). Since that time, it has been
studied in a diagnostic or therapeutic role in a variety of
disorders involving the pulmonary vasculature, including
primary pulmonary hypertension (27,28); persistent pulmo-
nary hypertension of the newborn (29,30); congestive heart
failure (31,32); intrinsic pulmonary disease, including pul-
monary fibrosis (33), scleroderma (34) and chronic obstruc-
tive pulmonary disease (35,36); acute respiratory distress
syndrome (37,38); and a variety of corrected and uncor-
rected congenital heart lesions (39).
Inhaled NO has been assessed as a predictor of PA
vasoreactivity in the cardiac catheterization laboratory and
as a long-term therapeutic agent (40). The latter role has
been limited by environmental concerns, difficulty in devel-
oping convenient delivery systems and potential toxicities.
Despite these limitations, successful use of this agent for
long-term therapy has been reported (41,42), and recent
attempts have been made to modify the NO molecule to
minimize toxicity as well as facilitate airway delivery (43).
The other use of NO—as a vasodilator in the catheteriza-
tion laboratory—has become increasingly popular. Recent
studies have demonstrated its efficacy as a screening vaso-
dilator agent and as a predictor of a safe response to oral
vasodilators in PPH (44,45). An advantage of iNO is the
avoidance of systemic hypotension, which can complicate
testing with oral and intravenous agents. Nitric oxide reacts
avidly with hemoglobin to yield the inactive metabolites
nitrite and nitrate in the pulmonary circulation, thus pre-
venting peripheral delivery of the inhaled agent (46).
Study objectives. We sought to evaluate the safety and
efficacy of iNO as a pulmonary vasodilator in the cardiac
catheterization laboratory in patients with both PPH and
SPH. Because previous evaluations of NO in pulmonary
hypertension mainly focused on the pediatric population,
the 42 patients we studied is the largest adult population
reported to date. Also unique to our study is the etiology of
SPH. Intrinsic pulmonary disease was present in 71%,
differing greatly from previous studies largely focusing on
patients with congenital heart lesions.
Nitric oxide was extremely well tolerated by both groups,
and no effect on systemic vascular tone was noted. Because
NO is a highly volatile substance, side-chain reactions with
oxygen can form toxic metabolites, including NO2. Levels
of NO2 remained low throughout inhalation during our
study.
All doses of NO used in this study (10, 20 and 40 ppm)
significantly lowered the mean PA pressure in patients with
pulmonary hypertension. Patients with higher RVEDP had
less reduction of PA pressures. To our knowledge, this
finding has not been described previously. Diastolic dys-
Figure 1. Response to iNO. The majority of the response is seen at 10 ppm of NO in both groups. However, patients with SPH show a trend toward a
further pressure reduction with higher doses of iNO.
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function and right ventricular failure is likely a marker of
long-standing pulmonary hypertension and may predict a
population less likely to respond to vasodilators.
In our whole study group, the mean PA pressure and
PVR significantly decreased during inhalation of NO. No
effect on aortic pressure or SVR was seen, confirming the
status of iNO as a selective pulmonary vasodilator. When
classified by etiology, patients with SPH tended to be less ill
than patients with PPH, with a better NYHA functional
class (2.55 vs. 2.94), a higher cardiac output (5.15 vs. 4.12
liters/min) and lower PVR (6.2 vs. 11.3 Wood U). Despite
these differences, the two groups responded to iNO at a
similar rate (78% in PPH vs. 83% in SPH). In the PPH
group, the majority of the drop in mean PA pressure
occurred at the lowest dose of NO (10 ppm), with little
additional diagnostic yield at higher doses. Similar results
have been reported by Sitbon et al. (47). In contrast, the
diagnostic yield was increased in patients with SPH at 20
and 40 ppm doses of NO. If only 10 ppm of NO was used
as a screening test, 7 (29%) of 24 responders would have
been missed, compared with only 2 (11%) of 18 responders
in the PPH group.
Mikhail et al. (48) previously measured venous and
arterial blood levels of vasoactive mediators in patients with
PPH and SPH; endothelin levels were found to be signif-
icantly elevated in both disorders. Compared with normal
control subjects, patients with PPH had lower NO levels
and patients with SPH had higher levels. This finding may
help to explain the observed trend toward a greater response
with higher doses of NO in SPH but no such effect in PPH.
Unexpected observations. The oxygen saturation in aortic
and pulmonary blood significantly improved during NO
inhalation in patients with SPH (92.4% to 95.9%, p 5
0.0004 and 66.2% to 71.7%, p 5 0.013, respectively). These
results concur with previously published reports; also, im-
proved oxygenation is a postulated benefit of iNO in this
patient group (49). Because iNO is delivered preferentially
to well-ventilated regions, the PAs supplying healthier lung
beds dilate and may result in improved ventilation–
perfusion matching.
To ensure that improved oxygenation was not, by itself,
responsible for the vasodilatory effect of NO, the results of
the 14 patients receiving both iNO and 100% oxygen by a
non-rebreather face mask were reviewed. Although minimal
changes in PVR and mean PA pressure (46 to 42.1 mm Hg)
were seen with 100% oxygen, a larger drop in PVR and a
significant drop in mean PA pressure (46 to 35.7 mm Hg,
p 5 0.02) was noted with 40 ppm of NO. Eleven (79%) of
14 patients were responders to NO, and 9 (64%) of 14
patients were responders to oxygen. If oxygen was used as
the sole screening tool for pulmonary vasoreactivity, three
responders would have been missed. One patient respond-
ing to oxygen would not have been identified using NO
alone. As Atz et al. (16) recently postulated, a combination
of NO and oxygen is likely to be the most sensitive
screening test for pulmonary vasoreactivity.
Table 4. Response of Patients With Primary and Secondary Pulmonary Hypertension to 40 ppm
of NO Compared With Baseline Value
Baseline 40 ppm NO p Value
PPH Group
Mean PAP (mm Hg) 51.5 6 19.8 40.1 6 18.9 ,0.001
PVR (Wood U) 11.3 6 8.2 8.1 6 7.9 ,0.001
Mean AoP (mm Hg) 105.2 6 15.8 105.1 6 15.6 0.940
SVR (Wood U) 24.0 6 5.7 23.4 6 7.8 0.504
Cardiac output (liters/min) 4.1 6 1.1 4.4 6 1.4 0.197
Aortic saturation (% oxygen) 91.2 6 4.8 94.0 6 4.0 0.014
PA saturation (% oxygen) 60.3 6 10.4 64.9 6 9.6 0.001
SPH Group
Mean PAP (mm Hg) 42.8 6 11.5 32.8 6 10.3 ,0.001
PVR (Wood U) 6.2 6 3.8 4.5 6 3.0 ,0.001
Mean AoP (mm Hg) 103.2 6 14.2 103.9 6 16.9 0.766
SVR (Wood U) 20.8 6 6.8 18.8 6 5.7 0.033
Cardiac output (liters/min) 5.2 6 1.8 5.3 6 1.5 0.306
Aortic saturation (% oxygen) 92.4 6 6.2 95.9 6 2.9 0.009
PA saturation (% oxygen) 66.2 6 10.6 71.7 6 7.6 0.001
Data are presented as the mean value 6 SD.
NO 5 nitric oxide; ppm 5 parts per million; other abbreviations as in Table 1.
Table 5. Response to Inhaled 100% Oxygen by Face Mask as
Compared With 40 ppm of NO
Baseline
100% Oxygen
by FM 40 ppm NO
Mean PAP
(mm Hg)
46.0 6 11.6 42.1 6 11.4 35.7 6 11.1
0.009 0.0002
PVR (Wood U) 8.0 6 4.6 6.8 6 3.7 5.7 6 3.8
0.003 0.0007
Aortic O2
saturation
(% oxygen)
90.8 6 6.8 99.3 6 1.5 95.4 6 3.4
0.0004 0.013
Responders 9/14 (64%) 11/14 (79%)
Data are presented as the mean value 6 SD, with p values below (p values are in
comparison to baseline values).
FM 5 face mask; NO 5 nitric oxide; O2 5 oxygen; PAP 5 pulmonary artery
pressure; PVR 5 pulmonary vascular resistance.
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Conclusions. This study confirms previous reports of the
safety and pulmonary selectivity of NO in the cardiac
catheterization laboratory for testing both patients with
PPH and those with SPH. Patients with pulmonary hyper-
tension appear to benefit hemodynamically from NO inha-
lation, regardless of their cause of pulmonary hypertension.
Our data suggest that for SPH, a dose effect may be present,
and use of higher doses may improve sensitivity of vasore-
activity screening. Concurrent testing with inhaled oxygen
provides additional information.
Future directions. Nitric oxide has been shown to be
useful in predicting a positive response to calcium channel
blocking drugs in PPH. Positive responders to calcium
channel blockers have survival benefit when treated long
term with these agents (50). McLaughlin et al. (51) recently
demonstrated that intravenous prostacyclin greatly im-
proved hemodynamic data and functional class in patients
with severely symptomatic SPH. Because this therapy is still
limited by expense and generalized availability, an alterna-
tive approach should be sought. Inhaled and nebulized
prostacyclin has shown recent promise and may be able to
significantly reduce costs, as well as systemic complications
related to other vasodilators (52–54). Several small trials
have demonstrated that calcium channel blockers can lower
pulmonary pressures in patients with chronic lung disease
(55–57). This is important, as elevated pulmonary pressures
have been shown to predict mortality in patients with
chronic obstructive pulmonary disease (58). Galloe et al.
(59) failed to see a benefit in terms of functional status or
mortality when using isradipine in an unselected (no mea-
surement of baseline pulmonary pressures or response to
vasodilators) group of patients with chronic obstructive
pulmonary disease. A large trial to study the effects of oral
vasodilators in patients responding to iNO is necessary at
this time.
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